Posted in | News | Business

Carlyle to Acquire TESCAN

Global investment firm Carlyle announced today that it has agreed to acquire a majority stake in TESCAN ORSAY HOLDING, a.s. (“TESCAN”), a leading manufacturer of electron microscopes and other high-tech scientific instruments. The terms of the transaction were not disclosed.

Founded in 1991 and headquartered in Brno, Czech Republic, TESCAN is a leading global developer and supplier of scanning electron microscopes, focused ion beam scanning electron microscopes, micro-CT scanners, and 4D scanning transmission electron microscopes. Its products are used by scientists to perform advanced material analysis in a wide range of large and growing end markets encompassing numerous R&D and industrial applications. TESCAN’s customer base comprises leading organisations across the public and private sectors, including blue-chip corporations and academic institutions.

TESCAN ORSAY HOLDING was formed in 2013 following the combination of TESCAN and ORSAY PHYSICS, two businesses which had pioneered major developments in the fields of scanning electron microscope technology and focused ion beam technology respectively. The group operates from 14 sites across the world, including two production facilities in Brno, Czech Republic, and Fuveau, France, which are responsible for its end-to-end in-house production, and has over 750 employees globally.

The Carlyle Europe Technology Partners (“CETP”) platform will aim to support TESCAN’s growth as a leading developer and supplier of cutting-edge analytical instruments by enhancing its position as a high-end manufacturer of devices targeting the most complex analysis use-cases, investing in new products, and further internationalizing the business. CETP has a longstanding history of investments in the sector and extensive experience working with and scaling similar technology businesses such as Cameca and Envea.

Vladimir Lasocki, Managing Director and Co-Head of the CETP investment advisory team, said: “TESCAN is a unique business and the last independent player in its sector. In this attractive primary opportunity, we recognize the potential to build on our domain knowledge of the analytical instruments market by working with the company to unlock the next level of growth as its large and varied end markets continue to expand and evolve. CETP has significant experience growing and internationalising leading European technology businesses, and we look forward to working with the TESCAN team on this exciting next step.”

Jaroslav Klíma, founder and acting CEO of TESCAN, said: “In Carlyle, we have found the perfect partner to support TESCAN’s next stage of growth. Their experience in the sector, combined with their track record of partnering with and growing businesses like ours, give me every confidence that TESCAN will continue to build on its impressive history of growth to date.”

The transaction is subject to customary regulatory approvals.

Source: https://www.tescan.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    TESCAN USA Inc.. (2023, January 04). Carlyle to Acquire TESCAN. AZoM. Retrieved on April 19, 2024 from https://www.azom.com/news.aspx?newsID=60634.

  • MLA

    TESCAN USA Inc.. "Carlyle to Acquire TESCAN". AZoM. 19 April 2024. <https://www.azom.com/news.aspx?newsID=60634>.

  • Chicago

    TESCAN USA Inc.. "Carlyle to Acquire TESCAN". AZoM. https://www.azom.com/news.aspx?newsID=60634. (accessed April 19, 2024).

  • Harvard

    TESCAN USA Inc.. 2023. Carlyle to Acquire TESCAN. AZoM, viewed 19 April 2024, https://www.azom.com/news.aspx?newsID=60634.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.